1. Home
  2. DRTS vs TVRD Comparison

DRTS vs TVRD Comparison

Compare DRTS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRTS
  • TVRD
  • Stock Information
  • Founded
  • DRTS 2015
  • TVRD 2017
  • Country
  • DRTS Israel
  • TVRD United States
  • Employees
  • DRTS N/A
  • TVRD N/A
  • Industry
  • DRTS Medical/Dental Instruments
  • TVRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • DRTS Health Care
  • TVRD Health Care
  • Exchange
  • DRTS Nasdaq
  • TVRD Nasdaq
  • Market Cap
  • DRTS 252.8M
  • TVRD 246.5M
  • IPO Year
  • DRTS N/A
  • TVRD N/A
  • Fundamental
  • Price
  • DRTS $3.12
  • TVRD $23.33
  • Analyst Decision
  • DRTS Strong Buy
  • TVRD Strong Buy
  • Analyst Count
  • DRTS 2
  • TVRD 3
  • Target Price
  • DRTS $8.00
  • TVRD $60.67
  • AVG Volume (30 Days)
  • DRTS 43.2K
  • TVRD 100.1K
  • Earning Date
  • DRTS 08-13-2025
  • TVRD 08-21-2025
  • Dividend Yield
  • DRTS N/A
  • TVRD N/A
  • EPS Growth
  • DRTS N/A
  • TVRD N/A
  • EPS
  • DRTS N/A
  • TVRD N/A
  • Revenue
  • DRTS N/A
  • TVRD N/A
  • Revenue This Year
  • DRTS N/A
  • TVRD N/A
  • Revenue Next Year
  • DRTS N/A
  • TVRD N/A
  • P/E Ratio
  • DRTS N/A
  • TVRD N/A
  • Revenue Growth
  • DRTS N/A
  • TVRD N/A
  • 52 Week Low
  • DRTS $1.93
  • TVRD $8.13
  • 52 Week High
  • DRTS $4.39
  • TVRD $34.31
  • Technical
  • Relative Strength Index (RSI)
  • DRTS 59.34
  • TVRD N/A
  • Support Level
  • DRTS $2.91
  • TVRD N/A
  • Resistance Level
  • DRTS $3.20
  • TVRD N/A
  • Average True Range (ATR)
  • DRTS 0.16
  • TVRD 0.00
  • MACD
  • DRTS -0.00
  • TVRD 0.00
  • Stochastic Oscillator
  • DRTS 68.70
  • TVRD 0.00

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: